Literature DB >> 24734958

The non-medical use of tramadol in the UK: findings from a large community sample.

A R Winstock1, R Borschmann, J Bell.   

Abstract

BACKGROUND: Prescription drug misuse has become a public health problem in several developed countries. In the UK, there has been no increase in people seeking treatment for prescription drug dependence, but there has been a progressive rise in fatal overdoses involving tramadol.
OBJECTIVES: To explore the source, motivations for use and patterns of use of tramadol in the UK.
METHODS: We conducted anonymous online survey of drug use and related behaviours as part of an ongoing drug trend monitoring initiative. We included questions assessing the patterns of use, source and function of tramadol.
RESULTS: UK Survey respondents (n = 7360) were predominantly young (mean age 29), and 90% reported being employed or studying. Less than 1% reported past-year use of heroin or methadone, but about 1/3 reported past-year use of cocaine. 326 (5% of respondents) reported having used tramadol in the preceding year, usually obtained by prescription but in 1/3 of cases from a friend; rarely from a dealer or from the internet. Most used the drug for pain relief, but 163 respondents (44%) reported using tramadol for reasons other than pain relief - particularly, using it to relax, to sleep, to get high or to relieve boredom. Nineteen per cent took doses higher than prescribed, and 10% reported difficulty discontinuing. Twenty-eight per cent combined tramadol with alcohol or other drugs to enhance its effect.
CONCLUSION: Misuse and sharing of tramadol, supplied by prescription, was common.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24734958     DOI: 10.1111/ijcp.12429

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  8 in total

1.  Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens.

Authors:  Yuki Asari; Yumiko Ikeda; Amane Tateno; Yoshiro Okubo; Takehiko Iijima; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2018-06-27       Impact factor: 4.530

2.  Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients.

Authors:  William J Kowalczyk; Jeremiah W Bertz; Landhing M Moran; Karran A Phillips; Udi E Ghitza; David H Epstein; Kenzie L Preston
Journal:  J Addict Med       Date:  2017 Nov/Dec       Impact factor: 3.702

Review 3.  Inappropriate opioid prescription after surgery.

Authors:  Mark D Neuman; Brian T Bateman; Hannah Wunsch
Journal:  Lancet       Date:  2019-04-13       Impact factor: 79.321

4.  The prevalence of visual symptoms in poppers users: a global survey.

Authors:  Andrew J Davies; Rohan Borschmann; Simon P Kelly; John Ramsey; Jason Ferris; Adam R Winstock
Journal:  BMJ Open Ophthalmol       Date:  2017-04-03

5.  High Rates of Tramadol Use among Treatment-Seeking Adolescents in Malmö, Sweden: A Study of Hair Analysis of Nonmedical Prescription Opioid Use.

Authors:  Martin O Olsson; Agneta Öjehagen; Louise Brådvik; Robert Kronstrand; Anders Håkansson
Journal:  J Addict       Date:  2017-12-24

6.  Moving on From Representativeness: Testing the Utility of the Global Drug Survey.

Authors:  Monica J Barratt; Jason A Ferris; Renee Zahnow; Joseph J Palamar; Larissa J Maier; Adam R Winstock
Journal:  Subst Abuse       Date:  2017-06-30

7.  Tramadol misuse in treatment-seeking adolescents and young adults with problematic substance use - Prediction of treatment retention.

Authors:  Eleonora Almér Herrnsdorf; Alexander Holmstedt; Anders Håkansson
Journal:  Addict Behav Rep       Date:  2022-07-11

8.  Nationwide Population-Based Study About Patterns of Prescription Opioid Use and Misuse Among Young Adults in Spain.

Authors:  Pilar Carrasco-Garrido; Carmen Gallardo-Pino; Isabel Jiménez-Trujillo; Valentín Hernández-Barrera; Soledad García-Gómez-Heras; Lidiane Lima Florencio; Domingo Palacios-Ceña
Journal:  Int J Public Health       Date:  2022-08-19       Impact factor: 5.100

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.